Keywords: exendin-4, enters, phase, ii, amylin, advanced, its

Exendin-4 enters Phase II

Article | 01 July 1999

Print This

Amylin has advanced its clinical development program for AC2993(synthetic exendin-4) into Phase II. A new, multidose study will look ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in